| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -59,705 | -38,646 |
| Stock-based compensation expense | 4,559 | 3,176 |
| Depreciation | 100 | 69 |
| Accretion of discounts on marketable securities | 2,258 | 1,564 |
| Non-cash lease income | 7 | 4 |
| Loss on sales and disposals of fixed assets, net | -37 | -38 |
| Other, net | 15 | 16 |
| Prepaid expenses and other assets | -3,005 | -3,167 |
| Accounts payable | -3,180 | -3,981 |
| Accrued expenses | 1,076 | 1,193 |
| Net cash used in operating activities | -56,388 | -36,568 |
| Purchases of property and equipment | 14 | 15 |
| Proceeds from sale of property and equipment | 31 | 30 |
| Purchases of marketable securities | 67,162 | 46,689 |
| Maturities of marketable securities | 118,873 | 86,374 |
| Net cash provided (used) by investing activities | 51,728 | 39,700 |
| Proceeds from the exercise of stock options and common stock issued under the 2020 eip | 113 | 113 |
| Net cash provided by financing activities | 113 | 113 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | 8 | 6 |
| Net increase (decrease) in cash and cash equivalents | -4,539 | 3,251 |
| Cash and cash equivalents at beginning of period | 40,876 | - |
| Cash and cash equivalents at end of period | 36,337 | - |
PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. (PMVP)